ArticleTranslational cancer research2025
Effect of periplocin on malignant behavior of oral squamous cell carcinoma cells.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral cancer ranks as the sixth most common malignancy worldwide, with a significantly higher prevalence among men aged 40 to 60 years than women. Previous studies have demonstrated that periplocin exhibits therapeutic potential by inhibiting cancer cell proliferation and inducing apoptosis across various cancer types. However, its role in oral squamous cell carcinoma (OSCC) and the associated molecular mechanisms remain insufficiently understood. In this study, we aimed to investigate the inhibitory effects of periplocin on the malignant behaviors of OSCC cells. Methods: MTS [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide] assay, colony formation assay, flow cytometry, and transwell assay were employed to assess the effects of periplocin on OSCC cell proliferation, apoptosis, cell cycle progression, and migration. Furthermore, proteomics analysis was conducted to identify differentially expressed proteins in OSCC cells treated with periplocin, providing insights into its mechanisms of action. Results: Periplocin significantly influenced OSCC cell proliferation, apoptosis, cell cycle dynamics, and migration. Proteomics data indicated that periplocin modulates apoptosis, protein binding, and DNA replication signaling pathways. Furthermore, bioinformatics analysis revealed a strong association between syndecan 1 ( Conclusions: The findings of this study indicate that periplocin exerts anti-OSCC effects by modulating key cellular processes in OSCC cells, offering a promising therapeutic avenue for OSCC management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.